The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development program (phase I trials) at Institut Gustave Roussy.
Myriam Kossai
No relevant relationships to disclose
Boris Duchemann
No relevant relationships to disclose
Caroline Caramella
No relevant relationships to disclose
Celine Boutros
No relevant relationships to disclose
Christophe Massard
No relevant relationships to disclose
Philippe Vielh
No relevant relationships to disclose
Anas Gazzah
No relevant relationships to disclose
Rastislav Bahleda
No relevant relationships to disclose
Eric Angevin
No relevant relationships to disclose
Antoine Hollebecque
No relevant relationships to disclose
Jean-Charles Soria
No relevant relationships to disclose
Benjamin Besse
No relevant relationships to disclose